Premedication to Reduce Amivantamab Associated Infusion Related Reactions
A phase 2 trial of Dexamethasone, Methotrexate, Amivantamab and Lazertinib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
Premedication to Reduce Amivantamab Associated Infusion Related Reactions is a phase 2 interventional study registered as NCT05663866 by Janssen Research & Development, LLC, with 68 participants enrolled, started 2023-05-18 and due to reach its primary completion in 2024-03-29. Interventions recorded: Dexamethasone, Montelukast, Methotrexate, Amivantamab and Lazertinib. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Shares Lazertinib, Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Lazertinib, Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Shares Lazertinib, Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Lazertinib, Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Shares Lazertinib, Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Shares Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Non-small-cell lung cancer and the tag pipeline.